PRTA announced that BMS communicated that the FDA granted Fast Track Designation to BMS-986446, an anti-tau antibody in P2 for Alzheimer's disease.

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of diseaseFast Track Designation recognizes the potential of ...

In this context, conductive foam serves as a key "electromagnetic pathway" connecting the battery module casing and the ...

Drug prices in the UK could rise amid 100 per cent tariffs on branded medicines, and pressure from US President Donald Trump ...

U.S. Customs and Border Protection officials detected cesium 137 in shipping containers of shrimp sent by PT Bahari Makmur Sejati to several U.S. ports. CBP officials flagged the potential ...

Hyundai Motor Company unveiled its most ambitious growth strategy today at the company’s first CEO Investor Day held outside ...

Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration today announced that Swedish Orphan Biovitrum AB ...

Drugmaker Pfizer has agreed to lower drug costs under a deal struck with President Donald Trump's administration ...

Trump said he will put tariffs of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on ...

It’s unclear how the new policy will affect Medicaid patients who often pay a nominal co-payment of a few dollars to fill ...